Your Health, We Care
Release date: 2025-04-11 10:55:49 Recommended: 41
The pricing of finerenone will be significantly diverse in 2025 depending on region, version, and health insurance policy differences.
The export price of the original drug produced by Bayer in Germany in the Japanese market is US$179 per box (10mg*100 tablets).
The price of the Lao Lucius version (10mg*30 tablets) is about $19. The price of the generic version of the Bangladesh Everest version is lower, with a package of 10mg*10 tablets costing about $51, but it should be noted that the way to obtain the generic drug is through compliance channels.
Finerenone in the Chinese market has been included in the medical insurance list, and the price of a single tablet has been reduced to about US$0.89 (calculated as a 100-tablet), which greatly reduces the burden on patients. In contrast, the U.S. market has higher prices, and packaging prices are volatile due to differences in specifications.
Packages with different dosages and number of tablets directly affect the total price. For example, the price of 10mg*100 tablets of the original drug is $179, while the unit price of a generic drug of the same dose may be higher if it is calculated in a pack of 10 tablets. In some regions, generic drugs are mainly packaged in 30 tablets or less, and the price is more flexible.
The role of finerenone in improving cardiorenal outcomes has been supported by several studies.
Finerenone is indicated for patients with chronic kidney disease associated with type 2 diabetes, particularly in the population with a urine albumin/creatinine ratio (UACR) of ≥30 mg/g, which may delay the progression of kidney disease and reduce the risk of cardiovascular events. Its precise inhibition of mineralocorticoid receptors reduces the side effects associated with sex hormones with conventional drugs.
The initial dose should be adjusted according to the patient's glomerular filtration rate (eGFR) and serum potassium level: 20 mg/day is recommended for eGFR ≥60 mL/min/1.73 m²; For eGFR of 25 to 60 mL/min/1.73 m² and serum potassium ≤ 5.0 mmol/L, the initial dose is 10 mg/day, which can be adjusted after 4 weeks. Serum potassium and eGFR should be monitored regularly during treatment to avoid the risk of hyperkalemia and worsening renal function.
Finerenone was shown to reduce the combined risk of cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure by 14%, and the risk of end-stage renal disease by 23%. Its unique non-steroidal structure makes it more targeted to heart and kidney tissues, and the incidence of hyperkalemia is lower than that of traditional mineralocorticoid receptor antagonists.
The balance between the price and efficacy of finerenone makes it an important choice for the treatment of diabetic nephropathy, and the introduction of medical insurance coverage and generic drugs has further expanded accessibility. In clinical practice, the dose needs to be optimized according to the individual situation of the patient to achieve the best treatment effect.
